Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
OpenAI Rejects Apple Trade Secret Theft Claims 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Qantas Near-Miss Raises Sydney Air Traffic Controller Fatigue Concerns 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
France Targets Shein, Temu With Fast-Fashion Fees 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Add as a preferred source on Google
MALVERN, Pa., March 06, 2018 -- PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the following investor conferences in March.
Cowen and Company 38th Annual Health Care Conference
Location: Marriott Copley Place, Boston
Date / Time: Tuesday, March 13, at 11 a.m. EDT
Needham & Company 17th Annual Healthcare Conference
Location: Westin New York Grand Central, New York City
Date / Time: Tuesday, March 27, at 9:30 a.m. EDT
About PhaseBio
PhaseBio Pharmaceuticals, Inc., is a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases. PhaseBio is leveraging its proprietary elastin-like polypeptide (ELP) biopolymer technology platform to develop therapies with the potential for less-frequent dosing and better patient compliance. PhaseBio’s lead development candidate, PB1046, is a first-in-class weekly vasoactive intestinal peptide (VIP) receptor agonist for the treatment of pulmonary arterial hypertension. The company is also developing PB2452, a reversal agent for the antiplatelet therapy ticagrelor. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA. For more information, please visit www.phasebio.com.
Media Contact:
Laura Bagby, 6 Degrees
(312) 448-8098
[email protected]
